Clinical Trials Directory

Trials / Completed

CompletedNCT03231995

Biomarkers for the Prognosis of Influenza in Children

Prospective Multicentre Study to Determine Respiratory Microbiome Biomarkers for the Prognostic of Clinical Course of Influenza in Children

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
145 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
5 Years
Healthy volunteers
Not accepted

Summary

Context: Seasonal influenza affects 2.5 to 3 million people each year in France, resulting in 1500 to 2000 severe cases seen in intensive care units. The severity of influenza is related to, among other things, its respiratory or neurological complications, observed especially in children. Early determination of the severity of influenza is a critical step to avoid in appropriate treatment and care for patients and to improve their survival. Viral, human but also environmental factors have been described as having an important role in determining this severity. Several studies suggest that the nasopharyngeal microbiome may be involved in the incidence and severity of respiratory viral infections. During influenza infection, the respiratory microbiota is significantly altered. In animal models, particularly murine models, the microbiota regulates the immune response to influenza virus infection. In a retrospective preliminary study, the investigators showed that the composition of the nasopharyngeal bacterial microbiota is different between children who develop a severe or moderate influenza. This difference was observed on respiratory specimens at admission to pediatric emergencies within two days of onset of symptoms. Hypotheses : * The respiratory microbiome is a determining factor in the clinical course of influenza infection (benign vs. severe with respiratory or neurological complication) * The respiratory microbiome can be used as a prognostic biomarker of the clinical course of influenza Originality: There are currently no clinical and / or virological markers to predict the clinical course of influenza infection. This study will define biomarkers of the respiratory microbiome to discriminate patients who will develop a severe influenza from those who will develop a moderate influenza. These prognostic biomarkers could be used to rapidly refer patients at risk to intensive care units, thus improving patient management and care. Moreover, at the fundamental level, this study will specify the role of the microbiome in the severity of influenza infection.

Conditions

Interventions

TypeNameDescription
BIOLOGICALCollection of nasopharyngeal specimen collected at D0, D1, D2 and D5.Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5. Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)

Timeline

Start date
2019-01-15
Primary completion
2022-04-20
Completion
2022-04-20
First posted
2017-07-27
Last updated
2022-06-08

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03231995. Inclusion in this directory is not an endorsement.